Tramadol/acetaminophen combination as add-on therapy in the treatment of patients with ankylosing spondylitis

doi:10.1007/s10067-012-2125-y

中山醫學大學機構典藏 CSMUIR > 醫學院 > 醫學研究所 > 期刊論文 > Item 310902500/17934

Please use this identifier to cite or link to this item: https://ir.csmu.edu.tw:8080/ir/handle/310902500/17934

Title:	Tramadol/acetaminophen combination as add-on therapy in the treatment of patients with ankylosing spondylitis
Authors:	Chang, Jhi-Kai Yu, Chen-Tung Lee, Ming-Yung Yeo, KJ Chang, I-Chang Tsou, Hsi-Kai Wei, James Cheng-Chung
Contributors:	醫學研究所
Keywords:	Acetaminophen;Ankylosing spondylitis;Clinical trial;Tramadol;Ultracet
Date:	2013
Issue Date:	2017-07-06T08:44:28Z (UTC)
ISSN:	0770-3198
Abstract:	Abstract This study aimed to determine the safety and efficacy of tramadol 37.5 mg/acetaminophen 325 mg combination tablets (Ultracet®) in patients with ankylosing spondylitis (AS). This was a 12-week, randomized, double-blind, placebo-controlled study. Sixty patients with active AS according to the Modified New York Criteria were enrolled. Active disease was defined by Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) for more than 3 at randomization. Subjects were randomized equally into two groups: the treatment group received aceclofenac plus Ultracet® one tablet twice a day, and the control group received aceclofenac plus placebo for 12 weeks. The primary endpoint was a difference of Assessment in Ankylosing Spondylitis (ASAS20) response criteria between two groups at week 12. At week 12, ASAS20 was achieved by 53.3 % of the aceclofenac plus Ultracet group and 31 % of the aceclofenac alone group (p = 0.047). For the pain visual analogue scale at week 12, there was a reduction of 45.6 % in aceclofenac plus Ultracet group and 25.7 % in the aceclofenac alone group (p = 0.087). There was no statistically significant difference between two groups in BASDAI, Bath Ankylosing Spondylitis Functional Index, Bath Ankylosing Spondylitis Global Index, Physician Global Assessment, spinal mobility, ESR, hs-CRP, and Ankylosing Spondylitis Quality of Life Questionnaire. A slight increase in total adverse events was noted with dizziness (7.5 vs 1.5 %), vertigo (4.5 vs 1.5 %), and nausea/vomiting (6 vs 0 %) in the Ultracet arm compared to placebo. The tramadol 37.5 mg/acetaminophen 325 mg combination tablet (Ultracet®) might has additional effect to nonsteroidal anti-inflammatory drugs in the treatment of patients with ankylosing spondylitis. It showed marginal benefit in pain and disease activity. However, a slight increase in minor adverse events was noted.
URI:	http://dx.doi.org/10.1007/s10067-012-2125-y https://ir.csmu.edu.tw:8080/ir/handle/310902500/17934
Relation:	Clinical Rheumatology March 2013, Volume 32, Issue 3, pp 341–347
Appears in Collections:	[醫學研究所] 期刊論文

Files in This Item:

File	Description	Size	Format
index.html		0Kb	HTML	256	View/Open

View Licence

Loading...